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The complete amino acid sequences of rat opioid receptors (designated as ROR-A and ROR-B) have been deduced by cloning and sequencing 
the cDNAs. The ligand-binding properties of ROR-A and ROR-B expressed from the cloned cDNAs in Chinese hamster ovary cells correspond 
most closely to those of the pharmacologically defined 6- and flu-opioid receptor subtypes, respectively. RNA blot hybridization analysis revealed 
that cerebrum and brainstem contain both ROR-A and ROR-B mRNAs, whereas neither ROR-A nor ROR-B mRNAs can be detected in 
cerebellum. 
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1. INTRODUCTION 
The opioid receptors exhibit a widespread distribu- 
tion throughout central and peripheral nervous systems 
and mediate pharmacological actions of opioid analge- 
sics, such as morphine, and physiological effects of en- 
dogenous opioid peptides derived from proopiomelano- 
cortin, preproenkephalin A and preprodynorphin [l]. 
At the molecular level, activation of the opioid recep- 
tors leads to inhibition of adenylate cyclase, activation 
of potassium channels and in~bition of calcium chan- 
nel activity through the action of guanine nucleotide- 
binding regulatory proteins (G-proteins) [2,3]. Pharma- 
cologically, the opioid receptors have been classified 
into at least three subtypes @, R and 6) on the basis of 
their difference in apparent affinity for opioid ligands 
[1,2]. However, there has been no direct evidence for the 
presence of molecularly distinct opioid receptor sub- 
types. Recently, the cDNA cloning of the mouse 6- 
opioid receptor has been reported [4,5]. In the present 
investigation, we have cloned two cDNAs encoding 
opioid receptors (designated as ROR-A and ROR-B) 
from rat cerebrum cDNA libraries and analyzed their 
ligand-binding properties by expression of the cloned 
cDNAs in Chinese hamster ovary (CHO) cells. The re- 
suits obtained indicate that ROR-A and ROR-B repre- 
sent the 6- and p-opioid receptor subtypes, respectively, 
and provide evidence indicating that distinct gene prod- 
ucts underlie pharmacologically different opioid recep- 
tor subtypes. 
2. MATERIALS AND METHODS 
2.1. Cloning of cDNAs 
A randomly primed and an oligo(dT)-porno cDNA library were 
constructed in phage &tlO using poly(A)+ RNA prepared [6,7] from 
adult Wistar rat cerebrum. They were screened with the mouse &- 
opioid receptor cDNA probe prepared as follows. Polymerase chain 
reaction (PCR) amplification was carried out using cDNA synthesized 
from poly(A)+ RNA prepared from adult ICR mouse brain and syn- 
thetic primers corresponding to nucleotide residues 77-101 (sense) and 
400-424 (antisense) of the mouse &opioid receptor cDNA [4]. The 
amplified PCR product was blunt-ended and cloned into the SmaI site 
of pBluescript SK(-) (Stratagene) to yield the plasmid, pMOR1. The 
0.35kilobase pairs (kb) BarnHI-PstI fragment from pMOR1 was 
used as a probe. cDNA inserts from clones positive to the probe were 
subcloned into pBluescript SK(-) and further analyzed. Five clones, 
including pROR1 and pRORIO, carried common SacI- and SmaI 
fragments, indicating that they are derived from identical mRNAs 
(ROR-A). cDNA inserts of 3 clones, including pRORl5, share a 
common restriction endonuclease map (BarnHI, XhoI, HindHI, Pstf 
and EcoRV) and are regarded as transcripts of identical mRNAs 
(ROR- B). cDNA clones pRORl0 and pRORl5 carry the entire 
protein- coding sequences and were used for sequence analysis [8,9]. 
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2.2. Expression of cDNAs and binding assay 
Abbreviations: G-proteins, guanine nucleotide-binding regulatory 
proteins; CHO cells, Chinese hamster ovary cells; DADLE, 
[o-Ala2,n-LRuS]enkephalin; DPDPE, [n-penicillamine2, n-penicillam- 
ine5]enkephalin; DSLET, [~Se~,~u5~nkephaiin-~r; DAGO, [D- 
Ala*,MePhe4,Glyo15~nkephalin. 
The - 2.1-kb EcoRV-XbaI fragment from pRORl0 and the 1.24- 
kb Aa&Hind111 fragment from pRORl5, containing the entire pro- 
tein-coding sequences, were inserted into the Hind111 site of an expres- 
sion vector pKNH [lo] to yield the plasmids, pRORSlO-1 and 
pRORS 15 1, respectively. CHO cells in culture were transfected with 
pRORSlO-1 or pRORSl5-1 cleaved with PvuI [1 I]. Clones expressing 
ROR-A (CRORIO-17) or ROR-B (CROR15-27) were isolated by 
Published by Elsevier Science Publishers B. K 311 
Volume 327, number 3 FEBSLETTERS August 1993 
screening G418-resistant clones by RNA blot hybridization analysis 
using each cDNA probe. 
Cells were washed with phosphate-buffered saline twice and homog- 
enized with a Dounce homogenizer in 50 mM Tris-HCI, pH 7.5. The 
homogenate was centrifuged at 1,000 x g for 10 min and the precipi- 
tate suspended in the same buffer, homogenized and centrifuged at 
1,000 x g for 10 min. The two supernatants were combined and centri- 
fuged at 20,000 x g for 30 min. The pellet was suspended in the same 
buffer and used for binding assays. [‘I-IJDADLE binding reaction was 
performed with membrane preparations (40-70 pg of protein per ml) 
in 0.2 or 1 .O ml of 50 mM Tris-HCl, pH 7.5, at 37’C for 45 min. After 
incubation, the samples were collected on GF/B filters (Whatman) and 
washed with 10 ml of 50 mM Tris-HCI, pH 7.5. The filters were then 
counted for radioactivity. 
2.3. RNA blot hybridization analysis 
Poly(A)’ RNAs prepared from adult Wistar rats were analyzed as 
described previously [12], except hat a 0.8% agarose gel was used and 
the filters were washed with 0.3 x SSC containing 0.1% SDS. The 
hybridization probes used were the - 3.0-kb cDNA insert of pROR1 
containing 1.08 kb of the protein-coding sequence of ROR-A and the 
- 2.8-kb cDNA insert of pROR15. The probes were labelled with 
[a-“P]dCTP by the random primer method [13]. Autoradiography was 
performed at -80°C for 10 days with an intensifying screen. An RNA 
ladder (Bethesda Research Laboratories) and the Hind111 cleavage 
products of phage /z DNA were used as size markers. 
3. RESULTS AND DISCUSSION 
cDNA libraries derived from rat cerebrum poly(A)’ 
RNA were screened by hybridization with a DNA frag- 
ment comprising a part of the mouse S-opioid receptor 
cDNA [4]. Two classes of cDNA clones (ROR-A and 
ROR-B) were isolated (see section 2.1) and sequence 
analysis revealed open reading frames that encode se- 
quences of 372 and 398 amino acids, respectively. Fig. 
1 shows the alignment of the deduced amino acid se- 
quences of the ROR-A and ROR-B proteins. Amino 
acid sequence comparison with each other revealed 61% 
identity. The ROR-A protein showed 97% sequence 
ROR-A 
ROR-B 
MEPVPSARAELQFSLLANVSDTFPSA--------FPSAN---------------------ARSASSLALAIAITALYSAVCAVCAV 
MDSS--------TGP-GNTSDCSDPLAQASCSPAPGSWLN 
TM-I 
ROR-A 
ROR-B 
GLLGNVLVMFGIVRYTKLKTATNIYI FNLALADAL,ATSTLPFQSAKYJ.J4ET&'FGELLCKAVLSIDYYNIfFTSIFTLTMMS?DRYIAVCH 
~~YRYTKMXTATNIYI~~QSFGTILCKIVISIDYYNMFI'SIFTT,CTM~RYIAVCH 
TM-II TM-III 
ROR-A 
ROR-B 
PVKALDFRTPAKAKLINICIbiVLASGVGVPIMVMAVTQPRDGAWCTLQFPSP SWYWrrrVTKICVFLFAFWPILIITVCYGLMLLRLRS 
PVKALDFRTPRNAKIVNVCNWILSSAIGLPVNFMATTKYRQZSIDCTLTFSHplWYWENLLK~CVFIF~RLKS 
TM-I” TM-” 
ROR-A 
ROR-B 
VRLLSGSKEKDRSLRRITRW~~IHIFVIVWTLVDINRRDPLWAALHLCIALGYANSSLNPVLYAFLDENFKRCFRQL 
VRMLSGSKEKDRNLRRITRMVLVWAVFIV~PIHIYVI~KALITIPET-TFQTVSWHFCIALGYTNSCLP~~Y~~DENFKRCFREF 
TM-VI TM-VII 
ROR-A CRAFCGGQEFGSLRRPRQATARERV-TACTPSDGFGGGAAA 312 
ROR-B CIpTSSTIEmNSTRVRQm-REHPSTANTVDRTNHQLENLEAETAPLP 398 
identity compared with the mouse 6-opioid receptor 
[4,5]. Seven transmembrane segments can be predicted 
in both of the ROR-A and ROR-B proteins, which is 
the characteristic structural feature of the G-protein- 
coupled receptors [14]. Furthermore, as with many of 
the G-protein-coupled receptors, the amino-terminal re- 
gion preceding the predicted transmembrane segment, 
TM-I, of these proteins contains potential sites of N- 
glycosylation [15]; 2 sites are found in ROR-A and 5 
sites in ROR-B. The putative cytoplasmic region be- 
tween TM-V and TM-VI, which has been shown to be 
involved in selective ffector coupling of the muscarinic 
acetylcholine receptor [16] and the adrenergic receptor 
[17], is conserved well between ROR-A and ROR-B. 
This observation may suggest that ROR-A and ROR-B 
couple with a similar type of G-protein. 
To examine whether the cloned cDNAs encode the 
opioid receptors, we performed expression studies. 
CHO cells were stably transformed with the cDNAs, 
and membrane preparations from the transformed 
clones were tested for the opioid ligand-binding proper- 
ties (Table I). Saturation analysis of [3H]DADLE bind- 
ing (Fig. 2) revealed that ROR-A and ROR-B are capa- 
ble of binding DADLE, an opioid agonist with a high 
affinity for both 6- and p-opioid receptor subtypes, with 
similar high affinities. The apparent Kd values for the 
other opioid ligands were obtained by measuring dis- 
placement of [3H]DADLE binding by increasing con- 
centrations of the ligands. As expected from the 97% 
amino acid sequence identity observed between ROR-A 
and the mouse S-opioid receptor, ROR-A showed li- 
gand-binding specificity of the &opioid receptor sub- 
type. DPDPE and DSLET, agonists with the highest 
affinity for the 6-opioid receptor subtype, showed high 
affinities for ROR-A (& = 28 nM and 12 nM, respec- 
tively), whereas the affinity of ROR-A for DAGO. an 
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Fig. 1. Alignment of the amino acid sequences of ROR-A (top) and ROR-B (bottom). The one-letter amino acid notation is used. Gaps (-) have 
been inserted to achieve maximum homology. Numbers of the amino acid residues at the right-hand end of the individual lines are given. The 
positions of the predicted transmembrane s gments (TM-I-VII) are indicated. The nucleotide sequences of ROR-A and ROR-B will appear in the 
DDBJ/GenBanMEMBL Nucleotide Sequence Databases under the accession umbers D16348 and D16349, respectively. 
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agonist selective for the y-opioid receptor subtype, was 
quite low (& = 2,240 nM). On the other hand, ROR-B 
exhibited much higher affinity for DAGO (K, = 4.0 
nM) and lower affinities for DPDPE (K,, = 1,900 nM) 
and DSLET (& = 142 nM) than ROR-A. Further- 
more, morphine and naloxone, which preferentially in- 
teract with the yopioid receptor subtype, exhibited af- 
finities for ROR-B higher than those for ROR-A. 
U.50488, selective for the K-opioid receptor subtype, had 
low afBnities for both ROR-A and ROR-B. The K, 
values obtained for ROR-A and ROR-B compare well 
with the reported I& values for the 6- and p-opioid 
16Hj DADLE fnM) 
B 
0 
I I I I I 
10 20 30 40 50 
[6Hj DADLE (nM) 
Fig. 2. Saturation analysis of [‘HIDADLE binding to membrane prep- 
arations from CRORlO-17 cells expressing ROR-A (A) and CRORIS- 
27 cells expressing ROR-B (B). Results of representative experiments 
are shown. The insets show Scatchard plots of the data. The non- 
specific binding (measured in the presence of excess amount of unla- 
belled DADLE) was less than 10% of the total radioactivity bound. 
No significant PHJDADLE binding could be detected in membrane 
preparations from non-tr~sf~t~ CHO cells. 
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Fig. 3. Autoradiograms of blot hybridization analysis of poly(A)+ 
RNA from rat tissues with the opioid receptor subtype ROR-A (A) 
and ROR-B (B) cDNA probes. Poly(A)+ RNA (30 fig each) prepared 
from kidney (lane I), cerebellum (lane 2), brainstem (lane 3) and 
cerebrum (lane 4) was analyzed as in section 2.3. The size markers are 
indicated. 
receptor subtypes [l&19], respectively. These results in- 
dicate that ROR-A and ROR-B correspond most 
closely to the pha~acologically defmed 6- and p- 
opioid receptor subtypes, respectively. 
Poly(A)+ RNA preparations from rat tissues were 
subjected to blot hybridization analysis (Fig. 3). Cere- 
brum and brainstem contain two RNA species of - 4.5 
and - 11 kb hybridizable with the ROR-A cDNA 
Table I 
L&and-binding properties of opioid receptor species expressed from 
cDNAs 
Ligand & (nM) 
ROR-A ROR-B 
DADLE 5.0 7.9 
DPDPE 28 1,900 
DSLET 12 142 
DAGO 2,240 4.0 
Morphine 1,260 5.3 
Naloxone 67 1.8 
U50488 >10,000 710 
Kd values for DADLE were obtained by Scatchard analysis using 
PHJDADLE (see Fig. 2). &values for the other ligands were obtained 
by measu~ng displacement of [%IjDADLE binding. 
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probe and an RNA species of - 16 kb hybridizable with 
the ROR-B cDNA probe. In contrast, neither ROR-A 
nor ROR-B mRNAs can be detected in cerebellum. In 
accord with this result are previous results obtained by 
autoradiographic studies with radioligands [20], which 
showed that the 6- and p-opioid receptor subtypes dis- 
tribute throughout he rat central nervous system except 
cerebellum. Multiple transcripts could be detected by 
the ROR-A cDNA probe, which is consistent with a 
recent report [5]. 
Our results obtained in this investigation indicate that 
the molecularly distinct opioid receptor subtypes, ROR- 
A and ROR-B, represent he pharmacologically defined 
6- and p-opioid receptor subtypes, respectively, and 
provide evidence indicating that pharmacologically dif- 
ferent opioid receptor subtypes are distinct gene prod- 
ucts. Pharmacologically, further refined classification of 
the opioid receptor subtypes has been suggested; 6 is 
classified into fil and 6, [21], and ,u into ,u, and ,uu2 [ 2]. 
Whether these sub-classifications are derived from dis- 
tinct genes or based on differences in post-translational 
modifications of ROR-A and ROR-B remains to be 
elucidated. 
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